Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$118.42
-0.9%		$125.92
$69.81
▼
$148.83
$10.32B0.961.43 million shs245,912 shs
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$249.47
-3.3%		$257.01
$197.81
▼
$495.55
$33.41B0.311.45 million shs287,630 shs
Biogen Inc. stock logo
BIIB
Biogen
$214.73
+1.9%		$209.57
$135.39
▼
$225.80
$31.75B0.171.20 million shs190,675 shs
Insmed, Inc. stock logo
INSM
Insmed
$127.02
-1.4%		$117.09
$90.39
▼
$212.75
$27.73B0.822.95 million shs402,553 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+0.43%+7.54%-6.31%+18.43%+33.85%
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-0.81%-3.52%+18.90%-10.85%-46.49%
Biogen Inc. stock logo
BIIB
Biogen
-0.83%-5.36%+1.74%+5.39%+46.75%
Insmed, Inc. stock logo
INSM
Insmed
+3.13%+1.71%-4.42%+33.17%-12.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$118.42
-0.9%		$125.92
$69.81
▼
$148.83
$10.32B0.961.43 million shs245,912 shs
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$249.47
-3.3%		$257.01
$197.81
▼
$495.55
$33.41B0.311.45 million shs287,630 shs
Biogen Inc. stock logo
BIIB
Biogen
$214.73
+1.9%		$209.57
$135.39
▼
$225.80
$31.75B0.171.20 million shs190,675 shs
Insmed, Inc. stock logo
INSM
Insmed
$127.02
-1.4%		$117.09
$90.39
▼
$212.75
$27.73B0.822.95 million shs402,553 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+0.43%+7.54%-6.31%+18.43%+33.85%
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-0.81%-3.52%+18.90%-10.85%-46.49%
Biogen Inc. stock logo
BIIB
Biogen
-0.83%-5.36%+1.74%+5.39%+46.75%
Insmed, Inc. stock logo
INSM
Insmed
+3.13%+1.71%-4.42%+33.17%-12.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.81
Moderate Buy$156.3832.06% Upside
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.88
Moderate Buy$382.9653.51% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$229.146.71% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$205.5261.80% Upside

Current Analyst Ratings Breakdown

Latest ABVX, ALNY, BIIB, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$242.00
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetReduce$165.00 ➝ $175.00
9/9/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$155.00
9/8/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$230.00 ➝ $260.00
9/3/2026
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$225.00 ➝ $245.00
9/2/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$455.00
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/25/2026
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$240.00 ➝ $260.00
8/25/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$376.00
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$4.80B6.95$2.68 per share93.02$5.97 per share41.79
Biogen Inc. stock logo
BIIB
Biogen
$10.03B3.16$22.87 per share9.39$124.45 per share1.73
Insmed, Inc. stock logo
INSM
Insmed
$606.42M45.74N/AN/A$3.46 per share36.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/21/2026 (Estimated)
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3846.4125.72N/A15.26%84.93%14.30%10/29/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6538.0413.332.358.32%11.18%6.88%10/29/2026 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$4.11N/A48.67N/A-76.94%-123.94%-44.30%10/29/2026 (Estimated)

Latest ABVX, ALNY, BIIB, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/21/2026Q2 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9585N/AN/AN/A$0.78 millionN/A
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.6724-$0.06+$0.6124-$0.06$395.50 million$425.49 million
7/30/2026Q2 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.63$1.84+$0.21$1.21$1.32 billion$1.29 billion
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
8.25
8.25
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Insmed, Inc. stock logo
INSM
Insmed
0.74
3.72
3.40

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Insmed, Inc. stock logo
INSM
Insmed
N/A

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6187.25 millionN/ANot Optionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664218.38 million213.80 millionOptionable

Recent News About These Companies

Exiting Insmed (INSM) Following Disappointing Key Drug Uptake
 |  insidermonkey.comhttps://www.insidermonkey.com/blog/exiting-insmed-insm-following-disappointing-key-drug-uptake-1835859/
Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
September 9 at 12:58 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4944348-insmed-incorporated-insm-presents-at-12th-annual-cantor-fitzgerald-global-healthcare
C WorldWide Group Holding A S Acquires 100,000 Shares of Insmed, Inc. $INSM
September 9 at 7:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-c-worldwide-group-holding-a-s-acquires-100000-shares-of-insmed-inc-insm-2026-09-09/
Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity
September 8 at 10:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4943809-insmed-a-strong-launch-and-a-much-bigger-peak-sales-opportunity
103,144 Shares in Insmed, Inc. $INSM Acquired by Nykredit A S
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-103144-shares-in-insmed-inc-insm-acquired-by-nykredit-a-s-2026-09-06/
Insmed stock holds near recent high as director sells shares and ERS data nears
September 4, 2026  |  ad-hoc-news.deA
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302869247.html
Nwam LLC Cuts Stock Position in Insmed, Inc. $INSM
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nwam-llc-cuts-stock-position-in-insmed-inc-insm-2026-09-04/
Wellington Management Group LLP Buys 144,849 Shares of Insmed, Inc. $INSM
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-buys-144849-shares-of-insmed-inc-insm-2026-09-04/
22,813 Shares in Insmed, Inc. $INSM Bought by AXQ Capital LP
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-22813-shares-in-insmed-inc-insm-bought-by-axq-capital-lp-2026-09-04/
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at ...
September 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/insmed-present-data-across-respiratory-110000706.html
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
September 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/insmed-to-present-data-across-its-respiratory-portfolio-including-new-late-breaking-arikayce-amikacin-liposome-inhalation-suspension-results-from-phase-3b-encore-study-at-the-european-respiratory-society-congress-2026-302868119.html
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?
September 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/do-you-believe-in-insmeds-insm-long-term-potential-despite-short-term-challenges-1826411/
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
September 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/insmed-insm-drug-launch-reshaping-084203303.html
Public Employees Retirement System of Ohio Takes $6.52 Million Position in Insmed, Inc. $INSM
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-takes-652-million-position-in-insmed-inc-insm-2026-09-02/
Insmed stock trades above $120 as TPIP program advances
September 1, 2026  |  ad-hoc-news.deA
Railway Pension Investments Ltd Takes Position in Insmed, Inc. $INSM
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-railway-pension-investments-ltd-takes-position-in-insmed-inc-insm-2026-09-01/
Headlands Technologies LLC Purchases 38,047 Shares of Insmed, Inc. $INSM
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-headlands-technologies-llc-purchases-38047-shares-of-insmed-inc-insm-2026-08-31/
Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Buy" from Analysts
August 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30993598
Insmed, Inc. (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-insmed-inc-nasdaq-insm-given-consensus-rating-of-buy-by-brokerages-2026-08-31/
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
August 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/liquidia-vs-insmed-pulmonary-stock-182200601.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$118.42 -1.04 (-0.87%)
As of 11:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$249.47 -8.53 (-3.31%)
As of 11:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen stock logo

Biogen NASDAQ:BIIB

$214.73 +4.00 (+1.90%)
As of 11:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insmed stock logo

Insmed NASDAQ:INSM

$127.02 -1.78 (-1.38%)
As of 11:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas